Previous close | 6.25 |
Open | 6.25 |
Bid | 6.20 |
Ask | 9.80 |
Strike | 2.50 |
Expiry date | 2024-08-16 |
Day's range | 6.25 - 6.25 |
Contract range | N/A |
Volume | |
Open interest | 20 |
BRISBANE, Calif., June 03, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and of
BRISBANE, Calif., May 30, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.
BRISBANE, Calif., May 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.’s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent).